Guide · Cannabis & Hemp · 2026 Dates

2026 Cannabis and Hemp Dates Compared: April 28, November 12, and December 11

Three 2026 dates change different rules for different products. This guide lines up the federal medical marijuana rescheduling, the federal hemp transition, and the Illinois and Missouri hemp laws, so each SKU and license is reviewed against the rule that actually changes on each date.

By Lincoln Square Law · 9-minute read

Why one “2026 deadline” is the wrong frame

Cannabis and hemp operators are working with three dates that are easy to blur together. April 28, 2026 changed the federal schedule for one defined slice of marijuana. November 12, 2026 starts a limited federal hemp phase, the Illinois Hemp Act, and Missouri’s first set of hemp-derived product rules. December 11, 2026 is when the rest of the federal hemp definition is scheduled to apply, and when part of Missouri’s law may follow it. Each date answers a different legal question. A plan built around a single deadline will apply the wrong rule to some products.

The practical approach is to treat each date as a gate. For each gate, name the rule that changes, the products or licenses it reaches, the owner who decides, and the evidence that supports the decision.

April 28: state medical marijuana and FDA-approved products moved to Schedule III

On April 28, 2026, the Drug Enforcement Administration published a final rule, effective the same day, placing three things in Schedule III of the Controlled Substances Act when they are in an FDA-approved product or subject to a state medical marijuana license: marijuana, marijuana extract, and naturally derived delta-9 tetrahydrocannabinols (91 Fed. Reg. 22714, adding 21 C.F.R. 1308.13(g)). Marijuana outside those categories remains in Schedule I. DEA states that synthetically derived THC remains in Schedule I and that hemp is unaffected.

The rule also created a registration pathway for state medical marijuana licensees as manufacturers, distributors, or dispensers (21 C.F.R. 1301.13(k)). Under the rule, a state medical license is conclusive evidence of state authorization, and a DEA registration is automatically suspended if the state license is suspended, revoked, or expires. DEA said it would make every effort to process applications filed within 60 days of publication within six months, and that applicants who filed within that window could operate under their state license while the application was pending. DEA registrations under the rule do not authorize non-medical activity.

What April 28 did not do. It did not move adult-use marijuana. A company with both medical and adult-use operations needs records that keep the two separate, from licenses and inventory to contracts and tax workpapers. The rule does not change hemp law, and it does not set any of the November or December hemp dates.

Tax consequences are a separate workstream. Section 280E of the Internal Revenue Code disallows deductions for trafficking in Schedule I or II substances (26 U.S.C. 280E). DEA’s rule states that state medical licensees will no longer be subject to that disallowance for covered activity, and it also states that nothing in the rule is a determination of federal tax liability. How to apply that to a particular return is a tax question for tax counsel. Our Schedule III and section 280E briefing addresses it separately.

The broader rescheduling proceeding. The same day, DEA noticed a formal hearing on its 2024 proposal to move marijuana generally from Schedule I to Schedule III, scheduled to begin June 29, 2026 and conclude by July 15, 2026 (91 Fed. Reg. 22777). As of this writing, we have not located a final rule from that proceeding. Until one is published, adult-use marijuana remains in Schedule I.

November 12: three hemp rules start on the same day

Federal hemp, limited phase. Section 781 of Public Law 119-37 rewrote the federal hemp definition, effective 365 days after its November 12, 2025 enactment. Section 2019 of Public Law 119-103 then provided that until December 11, 2026 the rewrite applies only to products containing cannabinoids that are not capable of being naturally produced by the Cannabis sativa L. plant. From November 12 through December 10, that is the only federal hemp change. Our federal hemp transition briefing covers the details.

Illinois Hemp Act. The Illinois Hemp Act, created by Public Act 104-0463 and codified at 410 ILCS 707, takes effect November 12, 2026 and replaces the Industrial Hemp Act (505 ILCS 89). The Illinois Department of Revenue has said that from that date a consumable or topical product with more than 0.4 milligrams of total THC per container is cannabis under Illinois law, may be sold only through the licensed cannabis system, and that the State plans to enforce on November 12 regardless of the federal delay. Illinois applies its full definition, including synthesized cannabinoids and the container limit, on November 12. Our briefing on Public Act 104-0463 explains the licensing and product rules.

Missouri, first track. Missouri’s Intoxicating Cannabinoid Control Act treats hemp-derived cannabinoid products as marijuana under Article XIV and takes effect November 12, 2026 for four categories: products with cannabinoids the plant cannot produce, products with synthesized plant-producible cannabinoids, smokable or vapeable raw flower containing any THCA, and solid edibles with hemp-derived delta-9 above natural concentrations (RSMo 195.900.11(1)(a)). Other hemp-derived products become subject that day to Missouri’s under-21 rule (RSMo 195.900.11(2)). Our Missouri briefing explains both tracks.

The three November 12 rules do not line up. A delta-8 gummy made by converting CBD is a useful hypothetical. Illinois counts delta-8 among its similar-effect cannabinoids and excludes synthesized cannabinoids, so the gummy is treated as cannabis in Illinois on November 12. Missouri’s first track reaches synthesized plant-producible cannabinoids on November 12. Federally, the product’s status from November 12 depends on whether its cannabinoids are capable of being naturally produced, a question the FDA lists required by section 781 were meant to inform and which, as of this writing, have not been published.

December 11: the scheduled second federal step

Section 2019 limits the federal rewrite only until December 11, 2026. Unless Congress amends section 2019 or section 781, the complete federal definition applies from that date. That includes the total-THC test counting THCA, the exclusion for plant-producible cannabinoids synthesized outside the plant, the limits for intermediate products, and the 0.4-milligram-per-container limit for final products (7 U.S.C. 1639o, as amended). The same law funds the federal government only through December 11 (Pub. L. 119-103, div. A, sec. 106(3)), so funding legislation will be moving near that date. A funding bill changes the hemp schedule only if it amends one of those sections.

December 11 may also matter in Missouri. For products outside Missouri’s four first-track categories, the Act applies only during periods when federal restrictions prohibit those products. With the federal delay, that period would begin December 11 for products the full federal definition excludes from hemp. How the Missouri provision treats products that federal law never prohibits is an open question.

A gate calendar that operators can use

Gate 1, April 28 (already passed). Confirm which activities are covered by a state medical license and which remain Schedule I. Confirm whether a DEA registration application was filed and its status. Send the tax question to tax counsel with the license facts.

Gate 2, November 12. For every hemp-derived SKU, record the federal limited-phase result, the Illinois result for Illinois sales, and the Missouri track for Missouri sales. Set internal cutoffs ahead of November 12 so shelves, websites, and distributor channels are cleared on time.

Gate 3, December 11. Rerun the federal classification under the full definition. Rerun Missouri second-track products. Confirm the law again in early December, because Congress could change it.

Each gate needs an owner, an evidence file, and a stop rule that tells staff when a product may not ship.

Contracts and inventory around the dates

Purchase orders that deliver near November 12 or December 11 deserve attention now. Supplier agreements can require disclosure of cannabinoid source and production method, access to batch records, notice of formulation changes, and cooperation in holds and returns. Customer agreements can address discontinued SKUs and regulatory changes. Those terms are recommendations, not legal requirements, but they turn an uncertain date into an agreed process. For medical licensees relying on the April 28 rule, diligence files should identify the state medical license that supports the classification, and representations should not be broader than the rule.

What to ask counsel before each gate

Which of our activities are covered by the April 28 rule, and is our DEA registration in order? For each hemp SKU, what is the result on November 12 federally, in Illinois, and in Missouri, and what changes on December 11? Which purchase orders, customer commitments, and printed packaging are exposed? Who will confirm the law in the week before each date?